Key Learning Objectives:

Review the clinical and pathophysiological features of polycythemia vera (PV)
Describe the characteristics of advanced PV
Discuss the pivotal RESPONSE trial of Jakafi® (ruxolitinib) in patients with PV who are resistant to intolerant to hydroxyurea, including primary outcomes, safety, and long-term data
Discuss the RESPONSE-2 trial of Jakafi® (ruxolitinib) in patients with PV without splenomegaly, including primary outcomes and safety data
Apply clinical concepts to 3 real-world case studies of patients with characteristics of advanced PV

Charina Toste NP

OptumCare Cancer Care